In silico investigation of extracellular domain of RAGE receptor interaction with A-box and B-box of HMGB1 protein
DOI:
https://doi.org/10.14720/abs.61.2.15889Keywords:
human HMGB1, human RAGE, HADDOCK software, cancer, sepsisAbstract
HMGB1 protein which is a non-histone chromosomal protein with two functional domains named A-box and B-box can also act as a signaling molecule after releasing from the cell and binding to the cell surface receptors such as RAGE. HMGB1 through its B-box domain binds to extracellular domain of RAGE and activates the signaling pathways involved in various pathological conditions like sepsis and tumor growth and metastasis. Interaction of recombinant HMGB1 A-box with RAGEantagonizes the RAGE activation by HMGB1. In the present study, interaction of human RAGE (hRAGE) extracellular domain (VC1C2) and B-box and A-box of human HMGB1 (hHMGB1) was investigated using a protein-protein docking software, HADDOCK. The results obtained were analyzed by PyMOL and LigPlot softwares. The results show B-box and A-box bind to different sites on the VC1domain of RAGE and one of the B-box binding points is a positively charged groove located on the V domain surface which is also a major binding site for another RAGE ligand, Advanced Glycation Endproducts (AGEs). The obtained results can be utilized to design new potent drugs for treatment of HMGB1-RAGE-related diseases such as cancer and sepsis.
Metrics
Downloads
References
de Vries, S.J., Bonvin, A.M., 2011. CPORT: a consensus interface predictor and its performance in prediction-driven docking with HADDOCK. PloS One, 6 (3), e17695. DOI: https://doi.org/10.1371/journal.pone.0017695
Deane, R., Du Yan, S., Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al., 2003. RAGE mediates amyloid-beta peptide transport across the blood- brain barrier and accumulation in brain. Nature medicine, 9 (7), 907-913. DOI: https://doi.org/10.1038/nm890
Gerlitz, G., Hock, R., Ueda, T., Bustin, M., 2009. The dynamics of HMG protein-chromatin interactions in living cells. Biochemistry and cell biology = Biochimie et biologie cellulaire, 87 (1), 127-137. DOI: https://doi.org/10.1139/O08-110
Goodwin, G.H., Sanders, C., Johns, E.W., 1973. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. European journal of biochemistry / FEBS, 38 (1), 14-19. DOI: https://doi.org/10.1111/j.1432-1033.1973.tb03026.x
He, S.J., Cheng, J., Feng, X., Yu, Y., Tian, L., Huang, Q., 2017. The dual role and therapeutic potential of high-mobility group box 1 in cancer. Oncotarget. DOI: https://doi.org/10.18632/oncotarget.17885
Huttunen, H.J., Fages, C., Kuja-Panula, J., Ridley, A.J., Rauvala, H., 2002. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer research, 62 (16), 4805-4811.
Koch, M., Chitayat, S., Dattilo, B.M., Schiefner, A., Diez, J., Chazin, W.J., Fritz, G., 2010. Structural basis for ligand recognition and activation of RAGE. Structure, 18 (10), 1342-1352. DOI: https://doi.org/10.1016/j.str.2010.05.017
Laraia, L., McKenzie, G., Spring, D. R., Venkitaraman, A. R., Huggins, D. J., 2015. Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. Chemistry & biology, 22(6), 689-703. DOI: https://doi.org/10.1016/j.chembiol.2015.04.019
Laskowski, R.A., Swindells, M.B., 2011. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. Journal of chemical information and modeling, 51 (10), 2778-2786. DOI: https://doi.org/10.1021/ci200227u
LeBlanc, P.M., Doggett, T.A., Choi, J., Hancock, M.A., Durocher, Y., Frank, F., Nagar, B., Fergu- son, T.A., Saleh, M., 2014. An immunogenic peptide in the A-box of HMGB1 protein reverses apoptosis-induced tolerance through RAGE receptor. The Journal of biological chemistry, 289 (11), 7777-7786. DOI: https://doi.org/10.1074/jbc.M113.541474
Litwinoff, E., Hurtado Del Pozo, C., Ramasamy, R., Schmidt, A.M., 2015. Emerging Targets for The- rapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clinical pharmacology and therapeutics, 98 (2), 135-144. DOI: https://doi.org/10.1002/cpt.148
Lotfi, S., Rabbani-Chadegani, A., Ghadam, P., 2013. Evidence for the binding affinity of daunomycin to HMGB1 protein in chromatin and in solution. International journal of biological macromole- cules, 52 206-211. DOI: https://doi.org/10.1016/j.ijbiomac.2012.09.024
Lotze, M.T., Tracey, K.J., 2005. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature reviews. Immunology, 5 (4), 331-342. DOI: https://doi.org/10.1038/nri1594
Malik, P., Chaudhry, N., Mittal, R., Mukherjee, T.K., 2015. Role of receptor for advanced glycation end products in the complication and progression of various types of cancers. Biochimica et biophysica acta, 1850 (9), 1898-1904. DOI: https://doi.org/10.1016/j.bbagen.2015.05.020
Morrow, J. K., Zhang, S., 2012. Computational prediction of protein hot spot residues. Curr Pharm Des, 18(9), 1255-1265. DOI: https://doi.org/10.2174/138920012799362909
Moult, J., Pedersen, J.T., Judson, R., Fidelis, K., 1995. A large-scale experiment to assess protein structure prediction methods. Proteins, 23 (3), ii-v. DOI: https://doi.org/10.1002/prot.340230303
Musumeci, D., Roviello, G.N., Montesarchio, D., 2014. An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. Pharmacology & therapeutics, 141 (3), 347-357. DOI: https://doi.org/10.1016/j.pharmthera.2013.11.001
Neeper, M., Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C., Elliston, K., Stern, D., Shaw, A., 1992. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. The Journal of biological chemistry, 267 (21), 14998-15004. DOI: https://doi.org/10.1016/S0021-9258(18)42138-2
Orlova, V.V., Choi, E.Y., Xie, C., Chavakis, E., Bierhaus, A., Ihanus, E., Ballantyne, C.M., Gahmberg, C.G., Bianchi, M.E., Nawroth, P.P., et al., 2007. A novel pathway of HMGB1-mediated inflam- matory cell recruitment that requires Mac-1-integrin. The EMBO journal, 26 (4), 1129-1139. DOI: https://doi.org/10.1038/sj.emboj.7601552
Palumbo, R., Sampaolesi, M., De Marchis, F., Tonlorenzi, R., Colombetti, S., Mondino, A., Cossu, G., Bianchi, M.E., 2004. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. The Journal of cell biology, 164 (3), 441-449. DOI: https://doi.org/10.1083/jcb.200304135
Palumbo, R., De Marchis, F., Pusterla, T., Conti, A., Alessio, M., Bianchi, M.E., 2009. Src family kinases are necessary for cell migration induced by extracellular HMGB1. Journal of leukocyte biology, 86 (3), 617-623. DOI: https://doi.org/10.1189/jlb.0908581
Ramasamy, R., Shekhtman, A., Schmidt, A.M., 2016. The multiple faces of RAGE--opportunities for therapeutic intervention in aging and chronic disease. Expert opinion on therapeutic targets, 20 (4), 431-446. DOI: https://doi.org/10.1517/14728222.2016.1111873
Schmidt, A.M., Vianna, M., Gerlach, M., Brett, J., Ryan, J., Kao, J., Esposito, C., Hegarty, H., Hurley, W., Clauss, M., et al., 1992. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. The Journal of biological chemistry, 267 (21), 14987-14997. DOI: https://doi.org/10.1016/S0021-9258(18)42137-0
Sorci, G., Riuzzi, F., Giambanco, I., Donato, R., 2013. RAGE in tissue homeostasis, repair and rege- neration. Biochimica et biophysica acta, 1833 (1), 101-109. DOI: https://doi.org/10.1016/j.bbamcr.2012.10.021
Taguchi, A., Blood, D.C., del Toro, G., Canet, A., Lee, D.C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al., 2000. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 405 (6784), 354-360. DOI: https://doi.org/10.1038/35012626
Tang, D., Kang, R., Zeh, H.J., 3rd, Lotze, M.T., 2010. High-mobility group box 1 and cancer. Biochi- mica et biophysica acta, 1799 (1-2), 131-140. DOI: https://doi.org/10.1016/j.bbagrm.2009.11.014
Tang, D., Kang, R., Zeh, H.J., 3rd, Lotze, M.T., 2011. High-mobility group box 1, oxidative stress, and disease. Antioxidants & redox signaling, 14 (7), 1315-1335. DOI: https://doi.org/10.1089/ars.2010.3356
Todorova, J., Pasheva, E., 2012. High mobility group B1 protein interacts with its receptor RAGE in tumor cells but not in normal tissues. Oncology letters, 3 (1), 214-218. DOI: https://doi.org/10.3892/ol.2011.459
van Zundert, G.C., Rodrigues, J.P., Trellet, M., Schmitz, C., Kastritis, P.L., Karaca, E., Melquiond, A.S., van Dijk, M., de Vries, S.J., Bonvin, A.M., 2016. The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. Journal of molecular biology, 428 (4), 720-725. DOI: https://doi.org/10.1016/j.jmb.2015.09.014
Wallace, A.C., Laskowski, R.A., Thornton, J.M., 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein engineering, 8 (2), 127-134. DOI: https://doi.org/10.1093/protein/8.2.127
Wang, J., Tochio, N., Takeuchi, A., Uewaki, J.I., Kobayashi, N., Tate, S.I., 2013. Redox-sensitive structural change in the A-domain of HMGB1 and its implication for the binding to cisplatin modified DNA. Biochemical and biophysical research communications, 441 701-706. DOI: https://doi.org/10.1016/j.bbrc.2013.10.085
Xue, J., Rai, V., Singer, D., Chabierski, S., Xie, J., Reverdatto, S., Burz, D.S., Schmidt, A.M., Hoffmann, R., Shekhtman, A., 2011. Advanced glycation end product recognition by the receptor for AGEs. Structure, 19 (5), 722-732. DOI: https://doi.org/10.1016/j.str.2011.02.013
Xue, J., Ray, R., Singer, D., Bohme, D., Burz, D.S., Rai, V., Hoffmann, R., Shekhtman, A., 2014. The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal- derived AGEs. Biochemistry, 53 (20), 3327-3335. DOI: https://doi.org/10.1021/bi500046t
Yamagishi, S., Takeuchi, M., Inagaki, Y., Nakamura, K., Imaizumi, T., 2003. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. International journal of clinical pharmacology research, 23 (4), 129-134.
Yan, S.S., Wu, Z.Y., Zhang, H.P., Furtado, G., Chen, X., Yan, S.F., Schmidt, A.M., Brown, C., Stern, A., LaFaille, J., et al., 2003. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nature medicine, 9 (3), 287-293. DOI: https://doi.org/10.1038/nm831
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H.E., Susarla, S.M., Ulloa, L., Wang, H., DiRaimo, R., et al., 2004. Reversing established sepsis with antagonists of endogenous high- mobility group box 1. Proceedings of the National Academy of Sciences of the United States of America, 101 (1), 296-301. DOI: https://doi.org/10.1073/pnas.2434651100
Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., Zhang, Y., 2015. The I-TASSER Suite: protein structure and function prediction. Nature methods, 12 (1), 7-8. DOI: https://doi.org/10.1038/nmeth.3213
Yang, J., Zhang, Y., 2015. I-TASSER server: new development for protein structure and function predictions. Nucleic acids research, 43 (W1), W174-181. DOI: https://doi.org/10.1093/nar/gkv342
Yatime, L., Andersen, G.R., 2013. Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. The FEBS journal, 280 (24), 6556-6568. DOI: https://doi.org/10.1111/febs.12556
Zhu, S., Li, W., Ward, M.F., Sama, A.E., Wang, H., 2010. High mobility group box 1 protein as a potential drug target for infection- and injury-elicited inflammation. Inflammation & allergy drug targets, 9 (1), 60-72. DOI: https://doi.org/10.2174/187152810791292872
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
How to Cite
